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Introduction 
 
In Hungary approximately 2,600 new cases of bladder cancer are 
diagnosed every year making it the fifth commonest cancer in men. 
Approximately 70% of these patients initially present with superficial 
bladder cancer (SBC). The standard treatment for patients with SBC is 
transurethral resection of the bladder tumour (TURBT), followed by 
adjuvant intravesical instillations with chemotherapy and/or 
immunotherapy (BCG). The probabilities of recurrence and 
progression in non muscle invasive bladder cancer at 5 years after 
standard treatment range from 31% to 78%. These rates illustrate the 
modest success of currently available treatments and underline the 
need for improved therapies. 
Oncolytic herpes simplex virus (HSV) vectors have shown promising 
efficacy against a wide variety of malignancies both in vitro and in 
vivo and clinical trials for patients with metastatic colorectal, head and 
neck, breast, and prostate cancer, melanoma, and glioma have been 
completed. Oncovex
GALV/CD
 is a third generation oncolytic herpes 
simplex virus 1 (HSV-1) that combines oncolysis with the expression 
of a highly potent pro-drug activating gene (yeast cytosine 
deaminase/uracil phospho-ribosyltransferase fusion) and the fusogenic 
glycoprotein from gibbon ape leukemia virus (GALV). 
Oncovex
GALV/CD
 virus also contains other mutations  to increase its 
efficacy. ICP34.5 region deletion results in tumour selective viral 
replication, in addition deletion of ICP47 region increases the 
antitumor immune response. Previous studies with Oncovex
GALV/CD
 
have shown enhanced cell killing and tumour shrinkage (in vitro and 
in vivo) within tumours derived from head and neck, colon, pancreas, 
lung and glioma tissue.  
Bladder cancer is potentially an ideal tumour model for novel therapies 
because intravesical delivery is able to expose the tumour to high 
concentrations of virus. In addition, the umbrella cell layer of the 
bladder (the luminal surface of the urothelium) is not rapidly dividing 
and should therefore be resistant to infection and lysis by replication-
competent oncolytic viruses, which selectively infect and replicate 
within rapidly dividing cells.  
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Objectives 
 
 Test the efficacy of OncovexGALV/CD in vitro on several transitional 
cell human bladder tumour cell lines (EJ, RT112, T24, VMCUB-I, 
TCCSUP-G, 5637, KU19-19). 
 Elucidate whether expression of fusogenic glycoprotein (GALV) from 
OncovexGALV/CD virus increases cytotoxic cell killing within these 
cells in vitro. 
 Test in vitro the efficacy of OncovexGALV/CD in the presence of 5-
fluorocytosine on these human bladder tumour cell lines.  
 Test in vitro the efficacy of OncovexGALV/CD in combination with 
conventional chemotherapies on human bladder tumour cell lines (EJ, 
T24, TCCSUP-G, KU19-19). 
 Set up a stable and reproducible rat orthotopic bladder tumour model 
that is suitable to evaluate the effectivity of different therapeutical 
options in vivo.  
 Test the in vitro the efficacy of OncovexGALV/CD on the rat bladder 
tumour cell line (AY-27) with the fusion and prodrug assay 
 Assess the effectiveness of QRT-PCR in vivo in detecting tumour 
growth using urine and tissue samples on the rat bladder tumour model. 
 Evaluate the effectivity of bioluminescence imaging technique in 
detecting tumour growth in vivo on the rat orthotopic bladder tumour 
model. 
 Evaluate in vivo the efficacy of OncovexGALV/CD on our previously 
developed rat orthotopic bladder tumour model 
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Materials and methods 
Oncovex
GALV/CD
 and Oncovex
GFP
 (as control backbone) virus were used 
in the study, which were previously described by Simpson et al. 
Human bladder transitional cell cancer (TCC) cells (EJ, T24, RT112, 
VMCUB-I, TCCSUP-G, 5637, KU19-19) and a rat bladder cancer cell 
line (AY-27) were studied.   
To study the effectivity of the fusogenic gene human TCC cells were 
infected with Oncovex
GALV/CD 
or Oncovex
GFP
 at different MOIs and 
incubated for 48 hours. Cells were then either fixed with 
glutaraldehyde and stained with Crystal Violet, or treated with MTS 
reagent and measured by densitometer.  
To study the effectivity of the prodrug activating gene human TCC 
cells were infected with Oncovex
GALV/CD 
or Oncovex
GFP
. After 30 
minutes the virus was removed, and media containing different 
concentrations of 5-FC was added. After 48 hours incubation the cell 
supernatant was centrifuged and heat inactivated at 60°C. The resulting 
supernatants
 
were added to fresh test cells and incubated for 48 hours. 
Cells were then either fixed with glutaraldehyde and stained with 
Crystal Violet, or treated with MTS reagent and measured by 
densitometer.  
The effect of combination of Oncovex
GALV/CD 
and chemotherapeutic 
agents on cell proliferation was assessed by calculating combination 
index (CI) values. Derived from the median-effect principal of Chou 
and Talalay the CI provides a quantitative measure of the degree of 
interaction between two agents. A CI of 1 denotes an additive 
interaction, >1 antagonism, and <1 synergy. Experiments were done as 
described for in vitro survival assay using 4, 2, 1, 0.5, and 0.25 times 
the calculated ED50 of each agent (Oncovex
GALV/CD
 and chemotherapy) 
in a constant ratio checkerboard design. After 48 hours incubation cells 
were treated with MTS reagent and measured by densitometer. CI 
values were calculated using CalcuSyn software. 
To set up the in vivo rat orthotopic bladder tumour model Fischer F344 
female rats were used. The animals were placed in a supine position 
and were anesthetised with Isoflurane. The catheter (18-gauge BD 
Venflon) was inserted into the bladder via the urethra. To facilitate the 
tumour seeding the bladder mucosa was damaged by instillation 0.1 N 
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hydrochloric
 
acid followed by a rinse with 0.1N sodium
 
hydroxide for 
neutralization. The bladder was washed five times with PBS and AY-
27 HVEM cells (1.5-2.5x10
6
 cells) were then instilled and maintained 
in the bladder
 
for 1 hour. After 1 hour the catheters were removed, and 
the rats were allowed
 
to void spontaneously. 
To detect tumour growth urine samples were collected by holding the 
rats in a metabolization cage for 1 hour on day 0,4,7,11,14 after tumour 
implantation. On the collected urine samples and on day 28 removed 
bladder tissues QRT-PCR (quantitative reverse transcription 
polymerase chain reaction) was performed. 
To detect tumour growth by bioluminescent imaging technique 1x106 
AY-27 HL-S cells (encoding luciferase enzyme) were injected 
subcutaneously to the flank of the rats. In regular timepoints D-
Luciferin Firefly
 
Potassium salt (150 mg/kg) was administered
 
and 
imaging was performed by the non-invasive IVIS bioluminescence 
imaging camera to detect luciferase enzyme activity. Results were 
analyzed
 
using the Xenogen
 
software, that provides visual 
photographic images of bioluminescence detection. 
To evaluate the effectivity of Oncovex
GALV/CD
 in vivo the animals were 
assigned into three treated groups after tumour implantation (day 0): 
either OncoVex
GALV/CD
+5-FC (N˚=10), OncoVexGALV/CD +PBS (N˚=10) 
or PBS+5-FC (control group) (N˚=8). Intravesical treatment of 
implanted tumours was carried out with OncoVex
GALV/CD 
on days 7, 14 
and 21 and with 5-FC on days 8, 9, 15, 16, 22 and 24 in the same 
manner. The bladders were removed on day 28 and assessed for 
tumour abundance by macroscopic and pathological evaluation.  
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Results 
 
Human bladder TCC cell lines are sensitive to viral HSV oncolysis, 
which is enhanced by the expression of GALV glycoprotein.  
A panel of 7 TCC cell lines were tested for viral HSV oncolysis. High 
viral replication of the oncolytic HSV (Oncovex
GALV/CD
) was observed 
in all 7 TCC cell lines. This HSV viral replication led to a strong 
tumour cytotoxicity effect which was detected by MTS assay at an 
MOI as low as 0.001.  
The expression of GALV glycoproteins enhanced this viral tumour 
selective killing in four out of the seven TCC cell lines (EJ, T24, 
VMCUB-I and 5637 cells) infected with Oncovex
GALV/CD
. GALV 
expression led to the formation of multinucleated syncytia which were 
then surrounded
 
with cells showing the more classic HSV-1-mediated 
effect. In vitro MTS assays were carried out where the formation of 
multinucleated syncytia increased the cytopathic effect of 
Oncovex
GALV/CD
 when compared to the control virus. Lower levels of 
MTS activity were seen with OncoVEX
GALV/CD
 on infected EJ (42-54% 
decrease in cell survival, P<0.000), T24 (35-45%, P<0.000), VMCUB-
I (36-37%, P<0.000) and 5637 (35% P<0.000) cells. This suggests that 
the presence of GALV gene increased tumour cell killing.  
Cytosine deaminase (CD)/uracil phospho-ribosyltransferase 
expression converts 5-FC to 5-FU metabolites that show active 
chemotherapeutic effect within human bladder TCC cell lines in 
vitro.  
Cytosine deaminase (CD)/uracil phospho-ribosyltransferase fusion 
metabolizes 5-FC
 
more efficiently than either gene alone. The cell
 
killing effects of 5-FC metabolites were studied on 7 human TCC cells 
with Oncovex
GALV/CD
 or Oncovex
GFP
 in the presence
 
or absence of 5-
FC. In EJ cells infected with Oncovex
GFP
 no cell death was seen with
 
or 
without 5-FC, whereas in the presence of both Oncovex
GALV/CD
 and 5-
FC effective cell killing was seen. Results were similar in a range of 
human bladder tumour cell
 
lines, including RT112 cells, TCCSUP-G 
cells, 5637 cells, KU19-19 cells. EJ cells showed 78% (P <0.000), 
RT112 and KU19-19 cells showed 70% (P <0.000), TCCSUP-G and 
5637 cells showed 53% (P<0.000) decrease in tumour cell survival on 
in vitro MTS assay. From these results we concluded that five out of 
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seven TCC cells were sensitive to metabolites of 5-FC after infection 
with Oncovex
GALV/CD
 (in the presence of 5-FC).  
Oncovex
GALV/CD
 and chemotherapeutic agent mitomycin C, show 
synergistic interaction on bladder TCC tumour cell lines, whereas 
coadministration with cisplatin or gemcitabine is antagonistic.  
From the currently used chemotherapeutic agents mitomycin C 
(MMC), cisplatin and gemcitabine were studied in combination with 
Oncovex
GALV/CD
. (We tested TCC cells including EJ, T24, TCCSUP-G 
and KU19-19.) We observed synergistic cell killing with 
Oncovex
GALV/CD
 and MMC on EJ (ED50 0.77 +/- 0.05), T24 (ED50 0.65 
+/- 0.07) and KU19-19 (ED50 0.78 +/- 0.01) TCC cells. However a 
combination of Oncovex
GALV/CD
 and cisplatin or gemcitabine was 
antagonistic on EJ, T24 and TCCSUP-G cells. 
In vivo rat orthotopic bladder tumour model was set up and 
Oncovex
GALV/CD
 treatment with or without 5-FC was studied on the 
model.  
To model in vivo human superficial bladder cancer a rat orthotopic 
bladder tumour model was used which was previously described by 
Xiao et al. AY-27 rat bladder transitional cell carcinoma cells that were 
previously tested for susceptibility for HSV replication were used in 
this model. AY-27 cells were stably transfected with the herpesvirus 
entry receptor (HVEM) and a clone was selected that supported 
infection with HSV. 
In vitro fusion assay (for testing GALV gene) results showed a 
reduction in tumour cell survival up to 30% in the new AY-27 HVEM 
cell clone when infected with Oncovex
GALV/CD 
compared to the 
Oncovex
GFP
 control. AY-27 HVEM cells were further tested in vitro in 
our prodrug assay, which showed that Oncovex
GALV/CD 
can metabolize 
5-FC within these cells, resulting in a decrease in tumour cell survival 
up to 81% when compared to controls.  
In the rat orthotopic bladder tumour model to facilitate tumour seeding, 
the bladder mucosa was conditioned with an acid rinse followed by 
neutralization with alkali and then AY-27 HVEM cells were implanted. 
After tumour seeding a high success rate of implantation was seen 
(>95%). The tumour implantation procedure was well tolerated by the 
animals and it was also reproducible.  
We planed to use QRT-PCR to demonstrate the presence of the HVEM 
receptor of the AY-27 rat bladder tumour cells as a marker for tumour 
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load in vivo. However while we obtained positive signals on bladder 
tissue QRT-PCR, signals using urine samples were insignificant, 
therefore tumour growth was detectable by QRT-PCR only on bladder 
tissue samples. 
Non-invasive IVIS bioluminescence imaging camera was also not 
suitable to detect tumour growth in vivo in this rat orthotopic bladder 
tumour model, due to host immune response to the luciferase 
expression.  
To study the efficacy of Oncovex
GALV/CD
 in vivo the tumour bearing 
animals were assigned into three treated groups after tumour 
implantation: either Oncovex
GALV/CD
+5-FC, Oncovex
GALV/CD
 +PBS or 
PBS+5-FC. The results showed an 84.5% reduction in average tumour 
volume in the presence of both Oncovex
GALV/CD
 and prodrug when 
compared to control (P=0.001) or Oncovex
GALV/CD
 virus alone 
(P=0.034). A smaller amount of tumour shrinkage seen with 
Oncovex
GALV/CD
 virus alone was not statistically significant when 
compared to control animals (46.4% tumour reduction) (P=0.13). The 
results were similar when comparing total bladder weights. On average 
the animals treated with Oncovex
GALV/CD
 +5-FC were 11.5g heavier 
than controls, suggesting that they were in a healthy condition 
compared to controls. 
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Conclusion 
 The transduction of human bladder tumour cells with viral fusogenic 
membrane glycoprotein (GALV) caused fusion and increased tumour 
cell killing in vitro using the OncoVEX
GALV/CD 
virus. 
 The transduction of human bladder tumour cells with prodrug 
activating (yeast cytosine deaminase/ uracil phospho-
ribosyltransferase) gene promoted active metabolism of 5-FC into 5-
FU and enhanced tumour cell killing in vitro using the 
OncoVEX
GALV/CD 
virus. 
 All human bladder tumour cell lines tested are susceptible to HSV 
oncolysis and showed enhanced tumour cell killing in at least one type 
(fusion or prodrug) of the assays when infected with OncoVEX
GALV/CD
 
virus.  
 The combination of oncolytic transduction of bladder tumour cells 
with viral fusogenic membrane glycoprotein (GALV) and a prodrug 
activating system (CD) can further increase tumour control in vitro.  
 The coadministration of OncoVexGALV/CD and mitomycin showed 
synergistic effect in vitro on human bladder tumour cells. 
 The coadministration of OncoVexGALV/CD with cisplatin or gemcitabine 
showed antagonistic effect in vitro on human bladder tumour cells. 
 AY-27 rat bladder tumour cells are rare exception in failing to support 
HSV entry and/or replication. 
 The transfected AY-27 HVEM cell line that contains the herpesvirus 
entry receptor supports HSV entry and replication. 
 The transduction of AY-27 HVEM cell line with viral fusogenic 
membrane glycoprotein (GALV) caused fusion and increased tumour 
cell killing in vitro using the OncoVEX
GALV/CD 
virus. 
 The transduction of AY-27 HVEM cell line with prodrug activating 
(CD) gene in the presence of 5-FC led to enhanced tumour control in 
vitro using the OncoVEX
GALV/CD 
virus.  
 The rat orthotopic bladder tumour model using AY-27 HVEM cell line 
was a stable and useful model that is suitable for further in vivo testing. 
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The percentage of tumour implantation using the orthotopic tumour 
model was strong (almost 95% after necropsy). 
 QRT-PCR on the removed bladder tissue samples (after necropsy) 
showed effective detection of tumour growth, but failed to detect a 
signal in urine from the same animals in vivo.  
 Non-invasive IVIS bioluminescence imaging camera was also not 
suitable to detect tumour growth in this rat orthotopic bladder tumour 
model.  
 OncoVexGALV/CD intravesical therapy with the combined transduction 
of viral fusogenic membrane glycoprotein (GALV) and a prodrug 
activating system (CD) in the presence of 5-FC prodrug led to 
enchanced local tumour control within the bladder in vivo in the rat 
orthotopic bladder tumour model. 
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